NCT05996107View on ClinicalTrials.gov

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2030

Conditions
Breast Cancer
Interventions
DRUG

Ribociclib

400 mg daily with a possibly dose reduction to 200 mg daily if required

RADIATION

Postoperative Radiation Therapy

50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal

Trial Locations (3)

44106

RECRUITING

UHCMC Seidman Cancer Center, Cleveland

48109

RECRUITING

University of Michigan, Ann Arbor

49519

RECRUITING

University of Michigan Health West, Wyoming

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER